Reuters logo
3 months ago
BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study
April 11, 2017 / 11:22 AM / 3 months ago

BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study

1 Min Read

April 11 (Reuters) - Immunovaccine Inc

* Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study evaluating immunovaccine's DPX-survivac with Merck's pembrolizumab

* Immunovaccine Inc - Merck is funding and contributing materials for non-randomized, open-label trial

* Immunovaccine Inc - Immunovaccine is contributing its product candidate as well as a related portion of analytical assays

* Immunovaccine Inc - trial is expected to enroll 42 subjects with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below